Notice of Changes to Funding Opportunities

• Notice of Correction in RFA-CA-21-060, "NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed)"
  (NOT-CA-22-015)
  National Cancer Institute
  

• Notice of Correction in RFA-CA-21-061, "NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 Independent Clinical Trial Required)"
  (NOT-CA-22-016)
  National Cancer Institute
  

• Notice of Correction in RFA-CA-21-062, "NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required)"
  (NOT-CA-22-017)
  National Cancer Institute
  

Notices of Special Interest

• Notice of Special Interest (NOSI): Accelerating Progress in Celiac Disease Research
  (NOT-AI-22-004)
  National Institute of Allergy and Infectious Diseases
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  

• Notice of Special Interest: Administrative Supplements on High Priority Topic Areas for NCCIH Grants
  (NOT-AT-22-002)
  National Center for Complementary and Integrative Health
  

• Notice of Special Interest (NOSI): Administrative Supplements for NCCIH Grants to Support Pain-Focused High Priority Research Areas
  (NOT-AT-22-003)
  National Center for Complementary and Integrative Health
  

• Notice of Special Interest: Expanding the Otitis Media Research Workforce: Focus on Early Stage Investigators
  (NOT-DC-22-001)
  National Institute on Deafness and Other Communication Disorders
  

• Notice of Special Interest (NOSI): Basic and Translational Oral Health Research Related to HIV/AIDS
  (NOT-DE-21-019)
  National Institute of Dental and Craniofacial Research
  

• Notice of Special Interest (NOSI): Availability of Administrative Supplements to INBRE Awards to Fund Research Collaborations
  (NOT-GM-22-001)
  National Institute of General Medical Sciences
  Office of Research on Women's Health
  

• Notice of Special Interest (NOSI): Limited Competition for Administrative Supplements to Accelerate the Development of a Translational Research Resource Platform for Advancing Maternal Precision Therapeutics
  (NOT-HD-21-051)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  

• Notice of Special Interest (NOSI): Examining Effects of HIV Pre-Exposure Prophylaxis (PrEP) on Heart, Lung, Blood, and Sleep Function
  (NOT-HL-21-025)
  National Heart, Lung, and Blood Institute
  

Funding Opportunities

• Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed)
  (PAR-22-071)
  National Cancer Institute
  Application Receipt Date(s): November 17, 2024
  
  

• Measures and Methods to Advance Research on Minority Health and Health Disparities-Related Constructs (R01 Clinical Trial Not Allowed)
  (PAR-22-072)
  National Institute on Minority Health and Health Disparities
  National Cancer Institute
  National Institute on Aging
  National Institute of Dental and Craniofacial Research
  National Institute of Environmental Health Sciences
  National Institute of Mental Health
  Office of Behavioral and Social Sciences Research
  Office of Disease Prevention
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
  (RFA-CA-22-001)
  National Cancer Institute
  Application Receipt Date(s): September 22, 2022
  
  

• Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
  (RFA-CA-22-002)
  National Cancer Institute
  Application Receipt Date(s): September 22, 2022
  
  

• Analysis, Technology, Leadership, Administration and Science (ATLAS) Center (U24 Clinical Trial Not Allowed)
  (RFA-DK-21-034)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): March 24, 2022
  
  

• Development of Advanced Analytical Methods for Analyzing Diastereomer Compositions in Oligonucleotides (U01) Clinical Trial Not Allowed
  (RFA-FD-22-013)
  Food and Drug Administration
  Application Receipt Date(s): February 7, 2022, by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.
  
  

• Research Centers in Minority Institutions (RCMI) (U54 Clinical Trials Optional)
  (RFA-MD-22-002)
  National Institute on Minority Health and Health Disparities
  Application Receipt Date(s): January 26, 2022
  
  

• Centers for Agricultural Safety and Health (U54)
  (RFA-OH-22-002)
  National Institute for Occupational Safety and Health
  Application Receipt Date(s): November 30, 2024